RecruitingPhase 4NCT04118387

Central Sleep Apnea : Physiologic Mechanisms to Inform Treatment

Central Sleep Apnea: Physiologic Mechanisms to Inform Treatment


Sponsor

VA Office of Research and Development

Enrollment

200 participants

Start Date

Jan 7, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

Central sleep apnea (CSA) is common in patients with heart failure and those using opioid analgesics. Unfortunately, effective treatment of central apnea remains elusive, pressure therapy given the modest efficiency of positive airway pressure therapy. The focus of this proposal is to identify mechanistic pathways to guide future therapeutic interventions for central sleep apnea based on the strong premise that multi-modality therapy will normalize respiration and hence mitigate adverse long-term consequences of CSA. The investigators' proposed studies will test combination therapies, including positive airway pressure (PAP) plus a pharmacological agent who have heart failure or are using opioid analgesics. The investigators anticipate that findings will inform future clinical trials to improve care and quality of life among Veterans suffering from central sleep apnea, which remains difficult to treat using existing approaches.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • Men and women Veterans with central sleep apnea, defined as Apnea Hypopnea Index (AHI)>15/hour with CAHI>5/hour, will be included in the experiments

Exclusion Criteria9

  • less than 18 years old
  • pregnant or breastfeeding female
  • have severe respiratory disease that require to be on oxygen
  • recent health event that may affect the ability to participate in the study,
  • Body Mass Index (BMI) is >40 kg/m2
  • significant insomnia
  • mental instability
  • recent health event that may affect sleep
  • if at any time the principal investigator (PI) identifies that a certain drug is not suitable, or are unable to use the device that is used to treat sleep apnea, will be not be allowed to participate in the study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAcetazolamide + supplemental oxygen + PAP therapy

Every participant will undergo measurement of the apneic threshold. The apneic threshold (AT) can be determined by inducing central apnea using non-invasive ventilation (NIV) or eliminating central apnea using supplemental CO2. The requisite change to induce central apnea is referred to as the CO2 reserve, which can be positive or negative. The central apnea index and the apneic threshold will be measured while participants receiving medication or oxygen (or both). In addition, participants will get PAP therapy during all the conditions.

DRUGZolpidem + PAP therapy

The central apnea index and the apneic threshold will be compared under two conditions: zolpidem or placebo. In addition, participants will get PAP therapy during both the conditions.

DRUGBuspirone + PAP therapy

The central apnea index and the apneic threshold will be compared under two conditions: buspirone or placebo. In addition, participants will get PAP therapy during both the conditions.


Locations(1)

John D. Dingell VA Medical Center, Detroit, MI

Detroit, Michigan, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04118387


Related Trials